Top Price Market
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Top Price Market

Investing

5 Small Biotech ETFs to Watch

by November 29, 2023
November 29, 2023
5 Small Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

1. Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Company Profile

AUM: US$81.96 million

The Global X Genomics & Biotechnology ETF tracks genomic science stocks, such as companies focused on gene editing, genomic sequencing, genetic medicine and therapy, computational genomics and biotechnology. This fund was first introduced to the market in April 2019 and invests at least 68 percent of its assets in mid- and small-cap companies.

There are 42 holdings in this biotech fund. Its top holdings include CRISPR Therapeutics (NASDAQ:CRSP) with a weight of 4.81 percent; Veracyte (NASDAQ:VCYT), weighing in at 4.5 percent; and Qiagen (NYSE:QGEN) at a 4.42 percent weightage.

2. ALPS Medical Breakthroughs ETF (ARCA:SBIO)

Company Profile

AUM: US$81.58 million

Launched in December 2014, the ALPS Medical Breakthroughs ETF tracks small- and mid-cap biotech stocks that have one or more drugs in either Phase II or Phase III US FDA clinical trials. Its holdings must have a market cap between US$200 million and US$5 billion.

There are 104 holdings in this biotechnology fund, with about 90 percent being small- to mid-cap stocks. Its top holdings include Vaxcyte (NASDAQ:PCVX) at a weight of 3.98 percent, Immunovant (NASDAQ:IMVT) at 3.71 percent and Cerevel Therapeutics (NASDAQ:CERE), weighing 3.46 percent.

3. ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB)

Company Profile

AUM: US$70.74 million

ProShares Ultra NASDAQ Biotechnology ETF was launched in April 2010 and is leveraged to the broad-based NASDAQ Biotechnology Index. The ETF Database says BIB is ideal “for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies.”

The top biotech stocks in this ETF are Vertex Pharmaceuticals (NASDAQ:VRTX) at a 7.78 percent weight, Amgen (NASDAQ:AMGN) at a 7.47 percent weight and Gilead Sciences (NASDAQ:GILD) at 7.47 percent.

4. Principal Healthcare Innovators ETF (NASDAQ:BTEC)

Company Profile

AUM: US$39.1 million

The Principal Healthcare Innovators ETF tracks US-listed healthcare stocks with a focus on those researching and developing innovative medicines and therapies. This fund was first introduced to the market in August 2016 and invests at least 80 percent of its assets in mid- and small-cap companies.

There are 227 holdings in this biotechnology fund. Its top holdings are Seagen (NASDAQ:SGEN) at 4.45 percent, Exact Sciences (NASDAQ:EXAS) at 3.37 percent and Alnylam Pharmaceuticals (NASDAQ:ALNY) at a 3.26 percent weightage.

5. Virtus LifeSci Biotech Products ETF (ARCA:BBP)

Company Profile

AUM: US$14.31 million

Launched in December 2014, the Virtus LifeSci Biotech Products ETF tracks biotech companies that have completed multiple human clinical trials and have received US Food and Drug Administration approval to sell and market a drug.

There are 55 holdings in this biotechnology fund, with about 60 percent being mid- to large-cap stocks. Its top holdings include Intercept Pharmaceuticals (NASDAQ:ICPT) at a weight of 3.41 percent, BridgeBio Pharma (NASDAQ:BBIO) at a weight of 3.35 percent and Rhythm Pharmaceuticals (NASDAQ:RYTM) at 2.84 percent.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Edward Sterck: Platinum on Track for Record Deficit, Price Catalysts Building
next post
Dutch version of controversial book on British royal family taken off shelves in Netherlands

You may also like

Helium Evolution Announces Farm-In Partner to Drill Second...

Freegold Intersects 4.63 g/t Au over 65.9 Metres...

Westport Announces Director Retirement

Jindalee to Participate in PDAC Convention and Redcloud’s...

Forum Intersects 2.25% U3O8 over 11.1 Metres on...

IsoEnergy to Acquire Anfield Energy, Strengthening US Uranium...

CleanTech Lithium PLC Submits Application for a Special...

How AI Will Transform 5 Key Industries

Crypto Market Recap: New Hampshire Launches First State...

Heliostar Metals Closes Bought Deal Equity Financing for...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Triumph Gold Updates Shareholders on Operations, Engages Market Maker, and Grants Options

    • Investing in Uranium ETFs: 9 Options for Uranium Exposure

    • Trump says 80% tariff on China ‘seems right’ ahead of weekend talks with Beijing

    • Crypto Market Recap: Bitcoin Breaks US$100,000 as ETF Inflows Rise, Coinbase Makes US$2.9 Billion Power Play

    • 7 Copper ETFs and ETNs

    Categories

    • Business (1,632)
    • Investing (4,786)
    • Politics (7,555)
    • Uncategorized (2)
    • World (6,138)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 toppricemarket.com | All Rights Reserved


    Back To Top